Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FSC Pediatrics announced the launch of Karbinal ER, the only 1st generation extended-release oral suspension antihistamine available in the US. Karbinal ER is an H1 receptor antagonist (antihistamine) indicated for two years of age and older.
Subscribe to our email newsletter
The availability of Karbinal ER provides physicians with a new, effective and easy to use treatment option for children with seasonal and perennial allergic rhinitis that need symptomatic relief for runny nose, sneezing, itchy nose or throat and itchy and watery eyes.
Allergic rhinitis affects the lives of over 50 million Americans as it is the third leading cause of chronic illness among children under the age of 18 years old in the U.S. Children account for 40 percent of those suffering from allergic rhinitis, resulting in 6.6 million pediatric diagnoses in 2012 alone.
Despite abundant treatment options, there still remains an overall unmet need and dissatisfaction with medications.
Based on an Asthma and Allergy Foundation of America survey, 88% say an important feature of prescription allergy medication is that it provides long-lasting relief of symptoms, 60% of all allergic rhinitis patients surveyed responded that they are very interested in finding a new medication, 31% are not fully satisfied with their current prescription medication and 26% are constantly trying new medications.
"The addition of Karbinal ER to our portfolio of products further demonstrates our commitment to meeting unmet needs of pediatric patients. We look forward to bringing Karbinal ER to the millions of pediatric allergy sufferers," said Peter W. Steelman, President and Chief Executive Officer at FSC Pediatrics.
"The launch of Karbinal ER demonstrates the continued success of our OralXR+ technology and is representative of Tris’ history of developing and manufacturing first-to-market liquid sustained-release products that fill significant unmet patient needs," added Ketan Mehta, President and CEO of Tris Pharma.
Steelman added, "We’re excited to be partnered with Tris Pharma to make this pleasant-tasting, extended-release liquid formulation of carbinoxamine, an antihistamine with years of proven safety and efficacy, available for patients as young as two years old."